Preclinical development of CodaLytic™, a codon-modified influenza virus, as a novel virotherapeutic agent for breast cancer immunotherapy

CodaLytic - Codagenix

Stawowczyk M; Zhao Y; Pfeffer K; Tafrova J; Rodriguez J; Yang C; Jahan N; Tasker S; Mueller S; Coleman JR; Kaufmann JK. Codagenix Inc.

Oct 10, 2022